Invitrogen Shows That Not All Life Science is Created Equal
Executive Summary
Invitrogen's performance in 2003 indicates some of the variables involved in determining who can weather the pinch in life sciences spending. The company's experiences indicate that some sectors of life sciences--and thus pharma and biotech R&D--are doing well even if others are not. Invitrogen's cell culture business in particular is growing 30% a year due to changes in the nature of the market, and its new fluorescent probe business, acquired earlier this year, is also doing well.